12 cases of brain disease after vaccines

Oct 24, 2006

The U.S. Food and Drug Administration said 12 cases of a neurological disorder have been reported following the application of a meningococcal vaccine.

The FDA said the 12 cases of Guillain-Barre Syndrome have been reported after administering of the vaccines, which are manufactured by French company Sanofi Pasteur, since October 2005, The Wall Street Journal reported Tuesday.

However, the FDA said sufficient evidence was not available to tie the vaccine to the disease and patients should continue to use it if instructed by their doctors.

The vaccines are used to prevent meningococcal disease, which causes bacterial meningitis -- an infection that attacks the lining of the brain and spinal cord. The disease affects about 1-in-100,000 young people every year.

Copyright 2006 by United Press International

Explore further: Data mining study identifies Twitter as lifeline for people with Coeliac Disease

add to favorites email to friend print save as pdf

Related Stories

When finding 'nothing' means something

Sep 25, 2014

Scientists usually communicate their latest findings by publishing results as scientific papers in journals that are almost always accessible online (albeit often at a price), ensuring fast sharing of latest ...

Recommended for you

Before you go... are you in denial about death?

5 hours ago

For most of us, death conjures up strong feelings. We project all kinds of fears onto it. We worry about it, dismiss it, laugh it off, push it aside or don't think about it at all. Until we have to. Of course, ...

UK court to rule on landmark 'pregnancy crime' case

6 hours ago

A British court is to rule on whether a woman committed a "crime of violence" against her child by drinking heavily during pregnancy, in a case that has raised concerns about criminalising mothers.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.